CFO
TMO icon

Callan Family Office’s Thermo Fisher Scientific TMO Stock Holding History

Callan Family Office’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.34M Sell
16,644
-1,852
-10% -$889K 0.16% 123
2026
Q1 		$9.09M Sell
18,496
-1,606
-8% -$872K 0.21% 91
2025
Q4 		$11.6M Buy
20,102
+3,757
+23% +$2.12M 0.25% 76
2025
Q3 		$7.93M Buy
16,345
+312
+2% +$145K 0.25% 83
2025
Q2 		$6.5M Buy
16,033
+4,146
+35% +$1.73M 0.21% 116
2025
Q1 		$5.91M Sell
11,887
-2,147
-15% -$1.16M 0.44% 50
2024
Q4 		$7.3M Buy
14,034
+9,012
+179% +$4.95M 0.46% 41
2024
Q3 		$3.11M Buy
5,022
+871
+21% +$516K 0.52% 37
2024
Q2 		$2.3M Buy
4,151
+2,864
+223% +$1.64M 0.44% 38
2024
Q1 		$748K Buy
1,287
+503
+64% +$282K 0.18% 50
2023
Q4 		$416K Buy
784
+97
+14% +$47K 0.1% 62
2023
Q3 		$348K Sell
687
-462
-40% -$246K 0.09% 65
2023
Q2 		$599K Sell
1,149
-1,138
-50% -$614K 0.16% 58
2023
Q1 		$1.32M Buy
2,287
+1,006
+79% +$567K 0.32% 47
2022
Q4 		$705K Buy
+1,281
New +$679K 0.23% 46

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Callan Family Office's TMO Position: Q2 2026 in Review

Callan Family Office reduced its Thermo Fisher Scientific (TMO) stake by 10% in Q2 2026, selling an estimated $889K and leaving 16,644 shares worth $8.34M. The position accounts for 0.16% of the portfolio, ranked #123.

Callan Family Office first reported a position in TMO in Q4 2022 and has held it in 15 quarters since. The position peaked at $11.6M in Q4 2025. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Callan Family Office held 16,644 shares of Thermo Fisher Scientific worth $8.34M as of Q2 2026.
  • Callan Family Office sold 1,852 Thermo Fisher Scientific shares in Q2 2026, an estimated $889K.
  • Thermo Fisher Scientific made up 0.16% of Callan Family Office's portfolio in Q2 2026, its #123 holding.
  • Callan Family Office first reported a position in Thermo Fisher Scientific in Q4 2022 and has held it in 15 quarters since.
  • Callan Family Office's Thermo Fisher Scientific position peaked at $11.6M in Q4 2025.
  • 2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.